Adagene Inc
ADAG1.820USD
-0.010-0.55%
收盤 12/19, 16:00（美東）報價延遲15分鐘
107.22M總市值
虧損本益比TTM
關於 Adagene Inc 公司
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Inc簡介
公司代碼ADAG
公司名稱Adagene Inc
上市日期Feb 09, 2021
CEOLuo (Peter)
員工數量138
證券類型Depository Receipt
年結日Feb 09
公司地址4F, Building C14, No. 218, Xinghu Street
城市SUZHOU
上市交易所NASDAQ OMX - NASDAQ BASIC
國家China
郵編- -
電話8651287773632
網址https://www.adagene.com/
公司代碼ADAG
上市日期Feb 09, 2021
CEOLuo (Peter)
Adagene Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Yuwen Liu
Ms. Yuwen Liu
Independent Director
Independent Director
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Mr. Zhao Qinghai, Ph.D.
Mr. Zhao Qinghai, Ph.D.
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ms. Gu (Vicky) Chunfang
Ms. Gu (Vicky) Chunfang
Senior Director of Finance
Senior Director of Finance
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.31M
-3.45%
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Lefei Sun
Mr. Lefei Sun
Director
Director
--
--
Dr. Li Min, Ph.D.
Dr. Li Min, Ph.D.
Independent Director
Independent Director
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
收入明細
FY2024
FY2023
FY2022
FY2021
FY2020
由於公司未披露，未能獲取相關數據
地區USD
名稱
營收
佔比
China (Mainland)
103.20K
0.00%
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月27日 週四
更新時間: 11月27日 週四
持股股東
股東類型
持股股東
持股股東
佔比
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
HSG Holding Ltd.
2.85%
其他
69.78%
持股股東
持股股東
佔比
General Atlantic LLC
8.03%
Olive Tree Capital
7.57%
WuXi AppTec Co, Ltd.
7.00%
Panacea Venture
4.77%
HSG Holding Ltd.
2.85%
其他
69.78%
股東類型
持股股東
佔比
Investment Advisor
13.29%
Venture Capital
12.37%
Private Equity
8.03%
Individual Investor
2.77%
Corporation
1.93%
Hedge Fund
0.35%
Research Firm
0.16%
Investment Advisor/Hedge Fund
0.02%
其他
61.08%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
34
16.13M
33.64%
--
2025Q3
35
16.13M
34.15%
+1.22M
2025Q2
33
14.91M
35.61%
-1.53M
2025Q1
31
16.44M
41.65%
-3.18M
2024Q4
29
17.99M
26.58%
+3.27M
2024Q3
27
14.73M
28.57%
+3.50M
2024Q2
28
11.22M
29.45%
-1.07M
2024Q1
30
12.30M
23.60%
+1.88M
2023Q4
27
7.12M
26.44%
-1.20M
2023Q3
33
8.32M
27.49%
-14.57K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
General Atlantic LLC
3.83M
8.12%
--
--
Jun 30, 2025
Olive Tree Capital
3.57M
7.57%
--
--
Feb 28, 2025
WuXi AppTec Co, Ltd.
3.98M
8.45%
--
--
Mar 31, 2025
HSG Holding Ltd.
1.34M
2.85%
--
--
Jun 30, 2025
Luo (Peter)
1.31M
2.77%
-46.66K
-3.45%
Feb 28, 2025
Impresa Management LLC
1.29M
2.74%
+1.29M
--
Feb 28, 2025
GP Healthcare Capital Co., Ltd.
910.00K
1.93%
+910.00K
--
Feb 28, 2025
Mill Creek Capital Advisors, LLC
199.61K
0.42%
--
--
Jun 30, 2025
Kamunting Street Capital Management, L.P.
126.03K
0.27%
+126.03K
--
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Adagene Inc的前五大股東是誰？
Adagene Inc的前五大股東如下：
General Atlantic LLC持有股份：3.83M佔總股份比例：8.12%。
Olive Tree Capital持有股份：3.57M佔總股份比例：7.57%。
WuXi AppTec Co, Ltd.持有股份：3.98M佔總股份比例：8.45%。
HSG Holding Ltd.持有股份：1.34M佔總股份比例：2.85%。
Luo (Peter)持有股份：1.31M佔總股份比例：2.77%。
General Atlantic LLC持有股份：3.83M佔總股份比例：8.12%。
Olive Tree Capital持有股份：3.57M佔總股份比例：7.57%。
WuXi AppTec Co, Ltd.持有股份：3.98M佔總股份比例：8.45%。
HSG Holding Ltd.持有股份：1.34M佔總股份比例：2.85%。
Luo (Peter)持有股份：1.31M佔總股份比例：2.77%。
Adagene Inc的前三大股東類型是什麼？
Adagene Inc 的前三大股東類型分別是：
General Atlantic LLC
Olive Tree Capital
WuXi AppTec Co, Ltd.
General Atlantic LLC
Olive Tree Capital
WuXi AppTec Co, Ltd.
有多少機構持有Adagene Inc(ADAG)的股份？
截至2025Q4，共有34家機構持有Adagene Inc的股份，合計持有的股份價值約為16.13M，占公司總股份的33.64% 。與2025Q3相比，機構持股有所增加，增幅為-0.51%。
哪個業務部門對Adagene Inc的收入貢獻最大？
在FY2024，--業務部門對Adagene Inc的收入貢獻最大，創收--，占總收入的--% 。
